Clinical Pharmacology in Drug Development

Aims & Scope

Clinical Pharmacology in Drug Development is an international, peer-reviewed, online publication focused on publishing high-quality clinical pharmacology studies in drug development which are primarily (but not exclusively) performed in early development phases in healthy subjects.

Acceptance of a manuscript in Clinical Pharmacology in Drug Development will be determined by scientific rigor and technical soundness rather than perceived importance of the presented results.

Thus, negative study results are explicitly not an obstacle for positive acceptance decisions.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.8

SJR (SCImago Journal Rank)

Year	Value
2024	0.691

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	38

Journal Rank

Year	Value
2024	8235

Journal Citation Indicator

Year	Value
2024	830

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

  Citation: 159

  Authors: Gilmour, Julie, Graham, Kenneth

• Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects

  Citation: 124

  Authors: Nobuko, Frank, Toshiyuki, Daniel, Jeanne

• Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

  Citation: 108

  Authors: Leo, Sreeraj, Gerhard, Gudrun, Bailuo, Sabine, Hans J., Klaus

• Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults

  Citation: 108

  Authors: Andreas H., Amit, David, Corrie, Kota, Shahzad, Donna, Christopher, William, Helene, Debra, Takao, Robert

• Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults

  Citation: 90

  Authors: Robert, Albert, Christine, Shahzad, Donna, Christopher, Kenneth, Helene, Diane, Anne, Takao, Amit

• Current Concepts in Methadone Metabolism and Transport

  Citation: 84

  Authors: Evan D.

• Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers

  Citation: 81

  Authors: M. Judith, Nigel P. S., Sebastiaan J. M., Allena J., Jyoti, Theresa T.

• Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

  Citation: 77

  Authors: Thomas, Jason, James, David L., Ching‐Lung, Johnson YN, Stephen A., Robert G., Bruce D.

• Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects

  Citation: 73

  Authors: Dirk, Oliver, Hans‐Peter, Helga, Holger

• Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

  Citation: 63

  Authors: Andi, Anat, Neal, John, Kathleen C.M., Frédéric

---